Increased prevalence of thyroid ultrasonographic alterations and thyroid autoimmunity in female hyperprolactinaemic patients on therapy with dopaminergic drugs;Aumentata prevalenza di alterazioni ecografiche e di autoimmunita tiroidea in donne iperprolattinemiche in terapia con farmaci dopaminergici

Recenti Progressi in Medicina

Volumn 90, Issue 3, 1999, Pages 147-151

  Giusti, Massimo ^a   Foppiani, Luca ^a   Fazzuoli, Laura ^a   Molinari, Ettore ^b   Guido, Roberta ^a   Valenti, Sandra ^a   Giordano, Giulio ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Autoimmunity; Dopaminergic drugs; PRL; Thyroid diseases

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; THYROID DISEASE; THYROID NODULE; THYROTROPIN BLOOD LEVEL;

ADOLESCENT; ADULT; AUTOIMMUNE DISEASES; AUTOIMMUNITY; BIOLOGICAL MARKERS; CHRONIC DISEASE; DOPAMINE AGONISTS; FEMALE; HUMANS; HYPERPROLACTINEMIA; MIDDLE AGED; PREVALENCE; PROLACTIN; THYROID GLAND; THYROID NODULE;

EID: 0032927865     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Giusti M, Gussoni G, Cuttica CM, Giordano G, the Italian Multicenter Slow Release Lanreotide Group. Effectiveness and tolerability of slow-release lanreotide treatment in active acromegaly: six-month report on an Italian study. J Clin Endocrinol Metab 1996; 81: 2089-97.
2. Tramontane D, Cushing GW, Moses AC, Ingbar SH. Insulin-like growth factor-I stimulates the growth of rat and thyroid cells in culture and synergizes the stimuation of DNA synthesis induced by TSH and Graves'-IgG. Endocrinology 1986; 119: 940-42.
3. Invitti C, Manfrini R, Romanini BM, Cavagnini F. High prevalence of nodular thyroid disease in patients with Cushing's disease. Clin Endocrinol 1995; 43: 359-63.
4. Goffin V, Shiverick KT, Kelly PA, Martial JA. Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen, and related proteins in mammals. Endocr Rev 1996; 17: 385-409.
5. Gona AG. Prolactin as a goitrogenic agent in amphibia. Endocrinology 1976; 81: 748-754.
6. Barbato MP. Goitre survey in Armidale and the New England region. Aust Nz J Med 1976; 6: 304-10.
7. Reber PM. Prolactin and immunomodulation. Am J Med 1993; 95: 637-44.
8. Nagy E, Berczi I, Wren GE, Asa SL, Kovaks K. Immunomodulation by bromocriptine. Immunopharmacology 1983; 6: 231-43.
9. Ferrari C, Boghen M, Paracchi A, Rampini P, Raiteri F, Benco R, Romussi M, Codecasa F, Mucci M, Bianco M. Thyroid autoimmunity in hyperprolactinaemic disorders. Acta Endocrinol (Copenh) 1983; 104: 35-41.
10. Solbiati L, Volterrani L, Rizzato G. The thyroid gland with low uptake lesion: evaluation by ultrasound. Radiology 1985; 155: 187-92.
11. Posner Bl. Studies of insulin, growth hormone and prolactin binding: tissue distribution, species variation and characterization. Endocrinology 1974; 95: 521-31.
12. Lowry OH, Rosenbrough N, Farr A, Randall R. Protein measurements with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
13. Minuto F, Barreca A, Del Monte P, Cariola G, Torre GC, Giordano G. Immunoreactive insulin-like growth factor 1 (IGF-1) and IGF-1 binding protein content in human thyroid tissue. J Clin Endocrinol Metab 1989; 68: 621-26.
14. Francis MJO, Hill DJ. Prolactin-stimulated production of somatomedin by rat liver. Nature 1975; 255: 167-68.
15. Landgraf R, Landgraft-Leurs MMC. Weissman A, Horl R, von Werder K, Scriba PC. Prolactin: a diabetogenic hormone. Diabetologia 1977; 13: 99-104.
16. Scanlon MF, Rodriguez-Arnao MD, Mc Gregor AM, Weightman DR, Lewis M, Cook DB, Gomez-Pan A, Hall R. Altered dopaminergic regulation of thyrotrophin release in patients with prolactinomas: comparison with other tests of hypothalamic-pituitary function. Clin Endocrinol 1981; 14: 133-43.
17. Molitch ME, Rebar RW, Barsano CP. Effect of human prolactin administration on gonadotropin and thyrotropin secretion in normal men. J Endocrinol Invest 1993; 16: 559.
18. Auernhammer CJ, Strasburger CJ. Effects of growth hormone and insulin-like growth factor 1 on the immune system. Eur J Endocrinol 1995; 133: 635.
19. Vanderpump MPJ, French JM, Appleton D, Tunbridge WMG, Kendall-Taylors P. The prevalence of hyperprolactinaemia and association with markers of autoimmune thyroid disease in survivors of the Whickham Survey cohort. Clin Endocrinol 1988;48:39.
20. st Annual Meeting 1989: 407.
21. Knobel M, Barca MF, Pedrinola F, Medeiros-Neto G. Prevalence of anti-thyroid peroxidase antibodies in autoimmune and nonautoimmune thyroid disordes in a relatively low-iodine environment. J Endocrinol Invest 1994; 17: 837.
22. Gerli R, Rambotti P, Nicoletti I, Orlandi S, Migliorati G, Riccardi C. Reduced number of natural killer cells in patients with pathological hyperprolactinemia. Clin Exp Immunol 1986; 64: 399.
23. Giusti M, Mazzocchi G, Mignone D, Tarditi W, Contessini M, Bessarione D, Giordano G. The effect of nomifensine on thyroid-stimulating hormone (TSH) in normal and hyperprolactinemic subjects. Neuroendocrinology 1983; 37: 406.
24. Persani L, Beck-Peccoz P. Medri G, Conti A, Faglia G. Thyrotropin alpha-and beta-subunit responses to thyrotropin-releasing hormone and domperidone in normal subjects and in patients with microprolactinomas. Neuroendocrinology 1991; 53: 411.